Raising the Bar on performance
- So as to force companies to get lean, activist investors employ the use of shareholder arbitrage.
- There is increasing selection in licensing and partnering opportunities, and a reduced margin for error.
- Market-authorization for one-time results in periodic reevaluation throughout the life cycle of the product.
- There is relentlessness in the compliance scrutiny, and globally, it has expanded beyond the illegal US off-label marketing going toward the penalty for multi-billion $ for corrupt practices which are foreign.
- The industry has been pressurized to respond to a customer base which is more diverse, with the engagement points being more.
- Country markets with a high potential are prone to operational challenges.
- In 2015, there have been a bump up in big selling drugs’ expirations.
- Although there is generalized budget austerity in Europe, there are also greater marketing pressures.
- Bottom line for pricing’s: profits for future are dependent on how the US freedom for pricing is maintained.
- Increased complexity in the requirements for clinical trial.
- New threats for competition from adjacent industries, CROS and Generics.
- Therapeutic categories have been crowded, campaigns increase the bill for marketing.
- Disruptive effect of the social media on physician/patient relationship, also the clinical trials’ accuracy.
- Engagement of patient groups formally while developing drugs, market access and regulatory approval.
What’s Hot
- Out-licensing and Biotech IPOs to big pharma: This year, the volume of the deal is higher. It has involved commercialization rights and asset swaps in multiple markets.
- Reliance on body’s own immune system to treat cancer.
- Use of chemotherapies to attack the growth of tumors.
- New drug combinations which is hot in Oncology.
- An understanding of how the complex procedures of the US ACA will make future drug utilization patterns effective.
- Ensuring patient-adherence to drugs using new IT technologies.
- The virtual sales pitch.
- Finding cost effective and efficient ways to manage the new reporting requirements for medicine promotions.
- Pressure on the “c-suit” to address tighter governance oversight.
What’s not
- Follow-on medicines in primary care.
- Deploying the field force using the blitzkrieg approach.
- Funding for pre-competitive, basic research.
- Broad-scope patent protection backslash that can be enforced across geographies.
- Big data without the applied analytics that can furnish useful insights on commercial strategy.